急性髓系白血病及其治疗对老年人生活质量和功能状态的影响。
The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults.
作者信息
Alibhai Shabbir M H, Leach Marc, Kermalli Husnain, Gupta Vikas, Kowgier Matthew E, Tomlinson George A, Brandwein Joseph, Buckstein Rena, Minden Mark D
机构信息
Department of Medicine, University Health Network, Toronto, Canada.
出版信息
Crit Rev Oncol Hematol. 2007 Oct;64(1):19-30. doi: 10.1016/j.critrevonc.2007.07.003. Epub 2007 Aug 31.
Although intensive chemotherapy (IC) may modestly improve survival compared to supportive care in older people with acute myeloid leukemia (AML), treatment may worsen quality of life (QOL) and functional status. We assessed QOL and functional status at baseline, 1 month, 4 months, and 6 months in 65 consecutive, English-speaking, patients age 60 or older with newly diagnosed AML. At baseline, functional status was high but QOL was negatively affected in global health and most QOL domains. Over time, QOL remained stable or improved in most patients and was generally similar between IC and non-IC groups. Basic activities of daily living (ADL) scores did not change over time, whereas instrumental ADL scores declined slightly regardless of treatment. Receiving IC does not appear to lead to worse QOL or functional status than more palliative approaches. This information may aid treatment discussions in older patients with AML.
尽管与支持性治疗相比，强化化疗（IC）可能会适度提高老年急性髓系白血病（AML）患者的生存率，但治疗可能会使生活质量（QOL）和功能状态恶化。我们评估了65例连续的、讲英语的、年龄在60岁及以上新诊断为AML的患者在基线、1个月、4个月和6个月时的QOL和功能状态。基线时，功能状态良好，但全球健康和大多数QOL领域的QOL受到负面影响。随着时间的推移，大多数患者的QOL保持稳定或改善，IC组和非IC组之间总体相似。日常生活基本活动（ADL）评分随时间未发生变化，而工具性ADL评分无论治疗如何均略有下降。与更姑息性的治疗方法相比，接受IC治疗似乎不会导致更差的QOL或功能状态。这些信息可能有助于老年AML患者的治疗讨论。
Zotero 插件